Genetic Epidemiology of Glioma-International Consortium


About this study

The purpose of this study is to identify common genetic variants contributing to the risk of glioma.  Evaluate gene-gene and gene-environmental interactions with strong biologic relevance to identify gene-gene and gene-environment interactions for glioma risk. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Histologically proven glioma will include:
    • GBM Cases must be identified at the site within 12 months of 1st glioma pathology date (biopsy or resection).
      • Consent, blood, and questionnaire must be completed within 18 months of 1st pathology date (biopsy or resection). 
    • Non-GBM cases must be identified at the site within 36 months of 1st glioma pathology date (biopsy or resection).
      • Consent, blood and questionnaire must be completed within 3.5 years of 1st pathology date.
      • 1st imaging date will also be collected so glioma patients who were diagnosed via imaging years before a surgery diagnosis (watchful-waiting) can be excluded if necessary at a later date.
  • Secondary glioma cases (recurrence and progression of disease are excluded).
  • Eligible Glioma Subtypes:
    • Glioma Histology (first pathology/surgery):
      • Astroblastoma
      • Astrocytoma, anaplastic
      • Astrocytoma, diffuse
      • Astrocytoma, fibrillary
      • Astrocytoma, gemistocytic
      • Astrocytoma, protoplasmic
      • Astrocytoma, unclassified
      • Ependymoma
      • Ependymoblastoma
      • Ependymoma, anaplastic
      • Ependymoma, myxopapillary
      • Ependymoma, tancytic
      • Giant cell glioblastoma multiforme
      • Glioblastoma mutliforme
      • Glioma, unclassified anaplastic
      • Glioma, unclassified
      • Gliomatosis cerebri
      • Gliosarcoma
      • Oligoastrocytoma
      • Oligodendroglioma
      • Oligodendroglioma, anaplastic
      • Oligostrocytoma, anaplastic
      • Pleomorphic xanthoastrocytoma
      • Subependyomoma
    • Glioma Topography (first pathology/surgery):
      • Brain Stem
      • Cerebellum
      • Cerebrum
      • Cranial Nerve, NOS
      • Cytology, ventricular fluid
      • Intracranial site, NOS
      • Suprasellar region
  • Age 18 to 80
  • Willing to complete questionnaire and donate 30 ml of blood and/or provide a saliva sample
    • The blood sample and questionnaire will be obtained from IRB# 12-003458.
  • English speaking participants only.

Control Accrual- (These Subjects will be obtained from IRB#08-007049)

  • Age 18 to 80
  • Willing to complete questionnaire and donate 30 ml of blood and/or provide saliva sample
  • English speaking participants only.
  • Never diagnosed with cancer.

Exclusion Criteria:

  • Pregnant women
  • Pediatrics 
  • Prisoners will be excluded

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Jenkins, M.D., Ph.D.

Closed for enrollment

Contact information:

Robert Jenkins M.D., Ph.D.


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions